# Chiara Zuccato

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 54 papers | 5,933 citations | 31 h-index | 56 g-index |
| 56 ext. papers | 6,563 ext. citations | 8.9 avg, IF | 5.62 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 54 | Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. *Nature Genetics*, **2003**, 35, 76-83 | 36.3 | 709 |
| 53 | Brain-derived neurotrophic factor in neurodegenerative diseases. *Nature Reviews Neurology*, **2009**, 5, 311-22 | 15 | 669 |
| 52 | Molecular mechanisms and potential therapeutical targets in Huntington's disease. *Physiological Reviews*, **2010**, 90, 905-81 | 47.9 | 616 |
| 51 | Normal huntingtin function: an alternative approach to Huntington's disease. *Nature Reviews Neuroscience*, **2005**, 6, 919-30 | 13.5 | 509 |
| 50 | Role of brain-derived neurotrophic factor in Huntington's disease. *Progress in Neurobiology*, **2007**, 81, 294-330 | 10.9 | 419 |
| 49 | A microRNA-based gene dysregulation pathway in Huntington's disease. *Neurobiology of Disease*, **2008**, 29, 438-45 | 7.5 | 292 |
| 48 | Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. *Journal of Neuroscience*, **2007**, 27, 6972-83 | 6.6 | 212 |
| 47 | Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. *Nature Neuroscience*, **2014**, 17, 513-21 | 25.5 | 210 |
| 46 | Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. *Journal of Neuroscience*, **2005**, 25, 9932-9 | 6.6 | 195 |
| 45 | Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. *Human Molecular Genetics*, **2002**, 11, 1953-65 | 5.6 | 173 |
| 44 | Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. *Brain Pathology*, **2008**, 18, 225-38 | 6 | 155 |
| 43 | Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. *Pharmacological Research*, **2005**, 52, 133-9 | 10.2 | 151 |
| 42 | Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. *Journal of Biological Chemistry*, **2008**, 283, 5780-9 | 5.4 | 144 |
| 41 | The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. *Neurobiology of Disease*, **2012**, 46, 41-51 | 7.5 | 136 |
| 40 | The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. *Neurobiology of Disease*, **2010**, 39, 28-39 | 7.5 | 115 |
| 39 | Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. *Journal of Biological Chemistry*, **2001**, 276, 14545-8 | 5.4 | 109 |
| 38 | Brain-derived neurotrophic factor in patients with Huntington's disease. *PLoS ONE*, **2011**, 6, e22966 | 3.7 | 95 |

| | | | |
|---|---|---|---|
| 37 | Human accelerated region 1 noncoding RNA is repressed by REST in Huntington's disease. *Physiological Genomics*, **2010**, 41, 269-74 | 3.6 | 83 |
| 36 | CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. *Molecular and Cellular Neurosciences*, **2008**, 39, 8-20 | 4.8 | 77 |
| 35 | An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. *Nature Neuroscience*, **2012**, 15, 713-21 | 25.5 | 76 |
| 34 | Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. *Cell Death and Differentiation*, **2015**, 22, 690-702 | 12.7 | 65 |
| 33 | Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. *Molecular Biology and Evolution*, **2008**, 25, 330-8 | 8.3 | 65 |
| 32 | Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. *Journal of Biological Chemistry*, **2002**, 277, 39594-8 | 5.4 | 63 |
| 31 | Huntington's disease. *Handbook of Experimental Pharmacology*, **2014**, 220, 357-409 | 3.2 | 60 |
| 30 | Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. *European Journal of Neuroscience*, **2003**, 18, 1093-102 | 3.5 | 54 |
| 29 | Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. *Neurobiology of Disease*, **2007**, 27, 108-16 | 7.5 | 51 |
| 28 | Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. *Molecular and Cellular Neurosciences*, **2008**, 39, 1-7 | 4.8 | 45 |
| 27 | NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. *Neurobiology of Disease*, **2012**, 48, 282-9 | 7.5 | 42 |
| 26 | Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data. *Genome Biology*, **2010**, 11, R9 | 18.3 | 39 |
| 25 | Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models. *Journal of Neurochemistry*, **2013**, 127, 22-35 | 6 | 33 |
| 24 | Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. *Journal of Biological Chemistry*, **2007**, 282, 24554-62 | 5.4 | 33 |
| 23 | Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. *Neurobiology of Disease*, **2013**, 50, 160-70 | 7.5 | 31 |
| 22 | Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop. *Journal of Biological Chemistry*, **2014**, 289, 32845-57 | 5.4 | 30 |
| 21 | Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease. *Pharmacological Research*, **2005**, 52, 140-50 | 10.2 | 30 |
| 20 | Turning REST/NRSF dysfunction in Huntington's disease into a pharmaceutical target. *Current Pharmaceutical Design*, **2009**, 15, 3958-67 | 3.3 | 26 |

| | | | |
|---|---|---|---|
| 19 | Shc3 affects human high-grade astrocytomas survival. *Oncogene*, **2005**, 24, 5198-206 | 9.2 | 23 |
| 18 | Analysis of the repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease. *Brain Pathology*, **2010**, 20, 96-105 | 6 | 17 |
| 17 | Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease. *Journal of Clinical Investigation*, **2019**, 129, 2390-2403 | 15.9 | 15 |
| 16 | Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones. *Neuropathology and Applied Neurobiology*, **2014**, 40, 899-910 | 5.2 | 12 |
| 15 | Pitfalls in the detection of cholesterol in Huntington's disease models. *PLOS Currents*, **2012**, 4, e505886e9a1968 | | 12 |
| 14 | From target identification to drug screening assays for neurodegenerative diseases. *Pharmacological Research*, **2005**, 52, 245-51 | 10.2 | 7 |
| 13 | The Huntington's Paradox. *Scientific American*, **2016**, 315, 56-61 | 0.5 | 6 |
| 12 | Prevalence of Huntington's disease in Southern Sardinia, Italy. *Parkinsonism and Related Disorders*, **2020**, 80, 54-57 | 3.6 | 6 |
| 11 | New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease. *PLoS ONE*, **2020**, 15, e0238037 | 3.7 | 4 |
| 10 | Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. *Cell Reports*, **2021**, 35, 108980 | 10.6 | 3 |
| 9 | The function of the neuronal proteins Shc and huntingtin in stem cells and neurons: pharmacologic exploitation for human brain diseases. *Annals of the New York Academy of Sciences*, **2005**, 1049, 39-50 | 6.5 | 2 |
| 8 | Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6. *SSRN Electronic Journal*, | 1 | 2 |
| 7 | Normal Function of Huntingtin **2014**, | | 2 |
| 6 | ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease. *Human Molecular Genetics*, **2021**, 30, 1175-1187 | 5.6 | 2 |
| 5 | The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities.. *Cell Death and Differentiation*, **2022**, | 12.7 | 1 |
| 4 | HTT Evolution and Brain Development. *Research and Perspectives in Neurosciences*, **2013**, 41-55 | | 1 |
| 3 | Huntingtin gene CAG repeat size affects autism risk: Family-based and case-control association study. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2020**, 183, 341-351 | 3.5 | 1 |
| 2 | Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. *Neurological Sciences*, **2021**, 42, 5177-5181 | 3.5 | 0 |

# List of Publications

1 Dans l'ombre de Huntington **2017**, N°90, 14-20